Wellington Management Group LLP Increases Position in Intellia Therapeutics, Inc. (NASDAQ:NTLA)

Wellington Management Group LLP raised its holdings in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA - Free Report) by 8.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 699,814 shares of the company's stock after purchasing an additional 55,051 shares during the period. Wellington Management Group LLP owned approximately 0.68% of Intellia Therapeutics worth $8,160,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ensign Peak Advisors Inc raised its holdings in Intellia Therapeutics by 2.9% in the 4th quarter. Ensign Peak Advisors Inc now owns 39,169 shares of the company's stock worth $457,000 after purchasing an additional 1,100 shares during the period. Allspring Global Investments Holdings LLC raised its holdings in Intellia Therapeutics by 14.0% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 12,863 shares of the company's stock worth $157,000 after purchasing an additional 1,582 shares during the period. Arizona State Retirement System raised its holdings in Intellia Therapeutics by 6.1% during the fourth quarter. Arizona State Retirement System now owns 28,006 shares of the company's stock valued at $327,000 after acquiring an additional 1,615 shares during the period. E Fund Management Co. Ltd. raised its holdings in Intellia Therapeutics by 10.0% during the fourth quarter. E Fund Management Co. Ltd. now owns 18,053 shares of the company's stock valued at $210,000 after acquiring an additional 1,634 shares during the period. Finally, Virtus ETF Advisers LLC raised its holdings in Intellia Therapeutics by 47.7% during the fourth quarter. Virtus ETF Advisers LLC now owns 5,242 shares of the company's stock valued at $61,000 after acquiring an additional 1,692 shares during the period. 88.77% of the stock is currently owned by hedge funds and other institutional investors.

Intellia Therapeutics Stock Performance

NASDAQ:NTLA traded up $0.51 during trading hours on Friday, reaching $8.09. The company's stock had a trading volume of 7,207,575 shares, compared to its average volume of 2,762,544. The company has a market capitalization of $837.99 million, a P/E ratio of -1.49 and a beta of 2.14. Intellia Therapeutics, Inc. has a 12 month low of $5.90 and a 12 month high of $28.18. The stock has a 50 day moving average price of $7.93 and a two-hundred day moving average price of $10.06.

Intellia Therapeutics (NASDAQ:NTLA - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($1.10) EPS for the quarter, topping analysts' consensus estimates of ($1.26) by $0.16. The business had revenue of $16.63 million during the quarter, compared to the consensus estimate of $11.39 million. During the same period last year, the firm earned ($1.12) EPS. The business's quarterly revenue was down 42.6% on a year-over-year basis. As a group, analysts predict that Intellia Therapeutics, Inc. will post -5.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on NTLA shares. Wedbush reissued a "neutral" rating and set a $7.00 price target (down from $10.00) on shares of Intellia Therapeutics in a report on Thursday, May 29th. The Goldman Sachs Group restated a "sell" rating and set a $9.00 price objective on shares of Intellia Therapeutics in a research report on Friday, February 28th. JPMorgan Chase & Co. restated a "neutral" rating and set a $13.00 price objective (down previously from $45.00) on shares of Intellia Therapeutics in a research report on Friday, February 28th. Wells Fargo & Company cut their price objective on Intellia Therapeutics from $60.00 to $50.00 and set an "overweight" rating for the company in a research report on Friday, February 28th. Finally, Citigroup dropped their price target on Intellia Therapeutics from $14.00 to $10.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Two investment analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, Intellia Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $34.95.

About Intellia Therapeutics

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.